Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
10.1001/jamaoncol.2021.2159 · doi-reference
Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic.
10.1002/pds.5029 · doi-reference
Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes.
10.1186/s13054-020-03400-9 · doi-reference
Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
10.2217/imt-2020-0067 · doi-reference
Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment.
10.1016/j.ctro.2020.04.006 · doi-reference
CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges.
10.1016/j.retram.2020.06.003 · doi-reference
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
10.1111/bjh.16863 · doi-reference
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.
10.1126/science.abc6027 · doi-reference
Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2.
10.1021/acs.jproteome.0c00397 · doi-reference
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
10.1001/jamaoncol.2020.2493 · doi-reference
Imatinib a Tyrosine Kinase Inhibitor: a potential treatment for SARS- COV-2 induced pneumonia.
10.1080/20905068.2020.1778417 · doi-reference
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
10.1056/nejmoa2012410 · doi-reference
The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19.
10.3389/fphar.2020.577678 · doi-reference
Management of patients with multiple myeloma during the COVID-19 pandemic.
10.1016/s2352-3026(20)30124-1 · doi-reference
Efficacy and tolerability of bevacizumab in patients with severe Covid-19.
10.1038/s41467-021-21085-8 · doi-reference
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
10.1056/nejmoa2031994 · doi-reference
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
10.1016/s0140-6736(21)00461-x · doi-reference
Anakinra for severe forms of COVID-19: a cohort study.
10.1016/s2665-9913(20)30164-8 · doi-reference
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.
10.1038/s41421-020-0153-3 · doi-reference
The impact of the SARS-CoV-2 infection, with special reference to the hematological setting.
10.1002/jmv.26197 · doi-reference
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19.
10.1016/j.ccell.2020.09.007 · doi-reference
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
10.1136/jitc-2020-001931 · doi-reference
Determinants of COVID-19 disease severity in patients with cancer.
10.1038/s41591-020-0979-0 · doi-reference
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy.
10.1038/s43018-021-00191-y · doi-reference
COVID-19 and immune checkpoint inhibitors: Initial considerations.
10.1136/jitc-2020-000933 · doi-reference
Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI).
10.1158/1557-3265.covid-19-s02-01 · doi-reference
Repurposing of anticancer drugs expands possibilities for antiviral and anti-inflammatory discovery in COVID-19.
10.1158/2159-8290.cd-21-0144 · doi-reference
Repurposing anticancer drugs for the management of COVID-19.
10.1016/j.ejca.2020.09.014 · doi-reference
Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue for the treatment of patients with COVID-19 (Review).
10.3892/ijo.2020.5159 · doi-reference
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology.
10.1200/go.20.00589 · doi-reference
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study.
10.1016/j.ejca.2020.09.027 · doi-reference
Influence of clinical characteristics and anti-cancer therapy on outcomes from SARS-CoV-2 infection: A systematic review and meta-analysis of 5,678 cancer patients.
10.1101/2020.12.15.20248195 · doi-reference
Artificial intelligence in COVID-19 drug repurposing.
10.1016/s2589-7500(20)30192-8 · doi-reference
Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.
10.1016/j.ejca.2021.02.027 · doi-reference
Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave.
10.1016/j.ejca.2021.01.040 · doi-reference
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study.
10.1016/j.ejca.2021.01.021 · doi-reference
COVID-19 in Older Individuals with Cancer: Problem and Potential Solutions.
10.1080/07357907.2020.1852567 · doi-reference
Treating Leukemia in the Time of COVID-19.
10.1159/000508199 · doi-reference
Hematological Abnormalities in COVID-19: A Narrative Review.
10.4269/ajtmh.20-1536 · doi-reference
Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies.
10.1016/j.bcmd.2020.102525 · doi-reference
